CClinicalTrials.gg
CompletedNCT04682938Updated Aug 10, 2022

The Prevalence and Characteristics of Adrenal Incidentaloma

An observational study in Prevalence and Adrenal Incidentaloma, sponsored by Chongqing Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 78 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-10.

Sponsored by Chongqing Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25,356
Ages
18 Years to 78 Years
Sex
All
01

Study summary

To investige the prevalence, characteristics and prognosis of adrenal incidentalomas in Chinese adults.

Read the detailed description

With the development of imaging detection technology and its wide application in clinic, the detection rate of adrenal incidentaloma (AI) has been greatly improved. Most AI are benign and do not have the function of autonomic hormone secretion, but about 20% of them have function and can secrete adrenal hormone autonomously. Studies based on biopsy reports show that the prevalence of AI is about 2%, and the prevalence of AI detected by CT scan is 1% - 4.5%. However, most of these studies are retrospective, and there may be selection bias and other confounding factors. There is no large sample prospective study on the prevalence of AI in the general population. The purpose of this study is to prospectively include patients with adrenal incidentaloma in community physical examination population, and evaluate their function and prognosis. The research results will provide new evidence for standardized diagnosis and treatment of adrenal incidentaloma in the future.

02

Conditions studied

  • Prevalence
  • Adrenal Incidentaloma

Keywords

  • Prevalence
  • characteristics
  • adrenal incidentaloma
03

In context

Adrenocortical Adenoma

40 studies on the registry are indexed under Adrenocortical Adenoma; 16 are open to participants now.

This study's enrollment of 25,356 is above the median of 101 across 22 observational studies indexed under Adrenocortical Adenoma.

Browse Adrenocortical Adenoma studies →

Lead sponsor

Chongqing Medical University is the lead sponsor of 75 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Chinese community adults

Inclusion criteria

·On weekdays, the first 100 individuals, aged 18 to 78 years, taking health checkup in the Community Health Examination Center were invited to take part in the study.

Exclusion criteria

Exclusion Criteria:

  • with known adrenal diseases;
  • with continuous steroids or drug treatment that might influence cortisol secretion ordexamethasone metabolism and could not be stopped
  • refuse to participate in the study.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25,356 participants (actual)
Patient registry
No
Biospecimen retention
None retained

Groups and cohorts

  • adrenal incidentalomas in Chinese community adults

    On weekdays, the first 100 individuals, aged 18 to 78 years, taking health checkup in the Community Health Examination Center were invited to take part in the study.

06

What researchers measure

Primary outcomes

  1. Prevalence and Characteristics of Adrenal Incidentaloma

    To investigate the prevalence and characteristics of Adrenal Incidentaloma in general population in China

    Time frame: 1 years

Secondary outcomes

  1. Steroid hormones in the function of Adrenal Incidentaloma

    prospectively evaluate potential predictive role of combined detection of multiple steroid hormones in the function of Adrenal Incidentaloma

    Time frame: 1 years

07

Study locations

1 site
  • the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
    Chongqing, Chongqing 400016, China
08

References and documents

Publications

  • Ichijo T, Ueshiba H, Nawata H, Yanase T. A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features. Endocr J. 2020 Feb 28;67(2):141-152. doi: 10.1507/endocrj.EJ18-0486. Epub 2019 Nov 7. PubMed 31694993 ↗
  • Lee JM, Kim MK, Ko SH, Koh JM, Kim BY, Kim SW, Kim SK, Kim HJ, Ryu OH, Park J, Lim JS, Kim SY, Shong YK, Yoo SJ; Korean Endocrine Society, Committee for Clinical Practice Guidelines. Clinical Guidelines for the Management of Adrenal Incidentaloma. Endocrinol Metab (Seoul). 2017 Jun;32(2):200-218. doi: 10.3803/EnM.2017.32.2.200. PubMed 28685511 ↗
  • Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016 Aug;175(2):G1-G34. doi: 10.1530/EJE-16-0467. PubMed 27390021 ↗
  • Jing Y, Hu J, Luo R, Mao Y, Luo Z, Zhang M, Yang J, Song Y, Feng Z, Wang Z, Cheng Q, Ma L, Yang Y, Zhong L, Du Z, Wang Y, Luo T, He W, Sun Y, Lv F, Li Q, Yang S. Prevalence and Characteristics of Adrenal Tumors in an Unselected Screening Population : A Cross-Sectional Study. Ann Intern Med. 2022 Oct;175(10):1383-1391. doi: 10.7326/M22-1619. Epub 2022 Sep 13. PubMed 36095315 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04682938
Lead sponsor
Chongqing Medical University
Responsible party
Qifu Li (Prof., Chongqing Medical University) — Principal investigator
First posted
Dec 24, 2020
Start date
Nov 20, 2020
Primary completion
Nov 30, 2021
Completion
Nov 30, 2021
Last update
Aug 10, 2022

Study contacts

Li Qifu, PhD
principal investigator · First Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion